Serum Asprosin, Metabolic Syndrome, and Cardiometabolic Risk in Rheumatoid Arthritis
Association of Serum Asprosin With Metabolic Syndrome and Cardiometabolic Risk in Patients With Rheumatoid Arthritis
Rheumatoid arthritis (RA) is a chronic inflammatory autoimmune disease associated with a significantly increased risk of cardiovascular disease and metabolic syndrome (MetS). Asprosin is a recently identified adipokine involved in glucose regulation, insulin resistance, and systemic inflammation, but its role in the cardiometabolic complications of RA remains incompletely understood.
The purpose of this case-control study is to evaluate and compare serum Asprosin levels among RA patients with metabolic syndrome, RA patients without metabolic syndrome, and healthy control individuals. The study will also assess the association between serum Asprosin concentrations, RA disease activity (DAS28-ESR), and various cardiometabolic risk indices (including TyG index, Atherogenic Index of Plasma, and Castelli risk indices).
Participants will undergo a comprehensive clinical assessment, disease activity scoring, physical function evaluation using the Health Assessment Questionnaire (HAQ), and laboratory investigations including fasting blood tests and serum Asprosin measurement via ELISA. Findings from this study may help clarify the pathophysiological role of Asprosin in RA and improve cardiometabolic risk stratification in affected patients.
研究概览
研究类型
注册 (估计的)
参与标准
资格标准
适合学习的年龄
- 成人
- 年长者
接受健康志愿者
取样方法
研究人群
描述
Inclusion Criteria:
- Adult patients aged 18 years or older.
- Diagnosis of rheumatoid arthritis fulfilling the 2010 ACR/EULAR classification criteria.
- Ability and willingness to provide written informed consent.
- Healthy controls: Age- and sex-matched individuals without rheumatoid arthritis or systemic inflammatory diseases.
Exclusion Criteria:
- Presence of other autoimmune diseases or overlap syndromes.
- Active acute or chronic infectious diseases.
- Pregnancy or lactation.
- Current malignancy or previous history of malignancy.
- Severe hepatic or renal impairment.
- Receipt of medications primarily prescribed for weight reduction or agents known to markedly alter lipid or glucose metabolism, other than standard rheumatoid arthritis therapy.
学习计划
研究是如何设计的？
设计细节
队列和干预
团体/队列 |
|---|
|
Rheumatoid Arthritis with Metabolic Syndrome
Adult patients diagnosed with rheumatoid arthritis fulfilling the 2010 ACR/EULAR classification criteria who also meet the NCEP ATP III criteria for metabolic syndrome (presence of 3 or more metabolic components).
Serum Asprosin levels and cardiometabolic risk indices will be evaluated.
|
|
Rheumatoid Arthritis without Metabolic Syndrome
Adult patients diagnosed with rheumatoid arthritis fulfilling the 2010 ACR/EULAR classification criteria who do not meet the NCEP ATP III diagnostic criteria for metabolic syndrome.
Serum Asprosin levels and cardiometabolic risk indices will be evaluated.
|
|
Healthy Controls
Age- and sex-matched healthy control individuals without rheumatoid arthritis, metabolic syndrome, or systemic inflammatory conditions, recruited for comparative assessment of baseline serum Asprosin levels.
|
研究衡量的是什么？
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Serum Asprosin Level
大体时间：Baseline
|
Serum asprosin concentration (measured in ng/mL) assessed via a commercial enzyme-linked immunosorbent assay (ELISA) kit to compare rheumatoid arthritis patients with metabolic syndrome versus rheumatoid arthritis patients without metabolic syndrome.
|
Baseline
|
合作者和调查者
研究记录日期
研究主要日期
学习开始 (估计的)
初级完成 (估计的)
研究完成 (估计的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
此信息直接从 clinicaltrials.gov 网站检索，没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求，请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改，我们的网站上也会自动更新.